HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Costelloe, C. M. Articles by Marom, E. M. Search for Related Content PubMed PubMed Citation Articles by Costelloe, C. M. Articles by Marom, E. M.

¹⁸F-FDG PET/CT as an Indicator of Progression-Free and Overall Survival in Osteosarcoma

¹ Department of Radiology, University of Texas M.D. Anderson Cancer Center, Houston, Texas; ² Department of Nuclear Medicine, University of Texas M.D. Anderson Cancer Center, Houston, Texas; ³ Department of Imaging Physics, University of Texas M.D. Anderson Cancer Center, Houston, Texas; ⁴ Department of Pathology, University of Texas M.D. Anderson Cancer Center, Houston, Texas; ⁵ Department of Orthopedic Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas; ⁶ Department of Pediatrics, University of Texas M.D. Anderson Cancer Center, Houston, Texas; and ⁷ Division of Biostatistics, University of Texas M.D. Anderson Cancer Center, Houston, Texas

Correspondence: For correspondence or reprints contact: Colleen M. Costelloe, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1273, Houston, TX 77030. E-mail: ccostelloe{at}mdanderson.org

The aim of our study was to retrospectively evaluate whether maximum standardized uptake value (SUV_max), total lesion gylcolysis (TLG), or change therein using ¹⁸F-FDG PET/CT performed before and after initial chemotherapy were indicators of patient outcome. Methods: Thirty-one consecutive patients who underwent ¹⁸F-FDG PET/CT before and after chemotherapy, followed by tumor resection, were retrospectively reviewed. Univariate Cox regression was used to analyze for relationships between covariates of interest (SUV_max before and after chemotherapy, change in SUV_max, TLG before and after chemotherapy, change in TLG, and tumor necrosis) and progression-free and overall survival. Logistic regression was used to evaluate tumor necrosis. Results: High SUV_max before and after chemotherapy (P = 0.008 and P = 0.009, respectively) was associated with worse progression-free survival. The cut point for SUV_max before chemotherapy was greater than 15 g/mL* (P = 0.015), and after chemotherapy it was greater than 5 g/mL* (P = 0.006), as measured at our institution and using lean body mass. Increase in TLG after chemotherapy was associated with worse progression-free survival (P = 0.016). High SUV_max after chemotherapy was associated with poor overall survival (P = 0.035). The cut point was above the median of 3.3 g/mL* (P = 0.043). High TLG before chemotherapy was associated with poor overall survival (P = 0.021). Good overall and progression-free survival was associated with a tumor necrosis greater than 90% (P = 0.018 and 0.08, respectively). A tumor necrosis greater than 90% was most strongly associated with a decrease in SUV_max (P = 0.015). Conclusion: ¹⁸F-FDG PET/CT can be used as a prognostic indicator for progression-free survival, overall survival, and tumor necrosis in osteosarcoma.

Key Words: molecular imaging • PET • PET/CT • ¹⁸F-FDG • osteosarcoma • survival • tumor necrosis

COPYRIGHT © 2009 by the Society of Nuclear Medicine, Inc.

Related articles in JNM:

This Month in JNM

JNM 2009 50: 11A-12A. [Full Text]